Your browser is no longer supported. Please, upgrade your browser.
ALKS Alkermes plc daily Stock Chart
ALKS [NASD]
Alkermes plc
Index- P/E- EPS (ttm)-0.80 Insider Own0.80% Shs Outstand158.90M Perf Week-2.03%
Market Cap2.71B Forward P/E38.45 EPS next Y0.44 Insider Trans-14.20% Shs Float157.56M Perf Month-6.16%
Income-126.30M PEG- EPS next Q0.00 Inst Own96.66% Short Float5.66% Perf Quarter-12.87%
Sales1.16B P/S2.33 EPS this Y-39.40% Inst Trans-0.30% Short Ratio7.00 Perf Half Y4.25%
Book/sh6.68 P/B2.53 EPS next Y344.44% ROA-7.00% Target Price18.90 Perf Year-6.78%
Cash/sh3.33 P/C5.09 EPS next 5Y- ROE-11.80% 52W Range11.98 - 21.88 Perf YTD-17.06%
Dividend- P/FCF- EPS past 5Y-43.30% ROI-12.80% 52W High-22.67% Beta1.20
Dividend %- Quick Ratio2.60 Sales past 5Y13.60% Gross Margin84.40% 52W Low41.24% ATR0.73
Employees2235 Current Ratio2.90 Sales Q/Q-11.60% Oper. Margin-11.60% RSI (14)47.71 Volatility2.65% 4.27%
OptionableYes Debt/Eq0.26 EPS Q/Q30.80% Profit Margin-10.90% Rel Volume1.00 Prev Close16.92
ShortableYes LT Debt/Eq0.26 EarningsJul 29 BMO Payout- Avg Volume1.28M Price16.92
Recom3.10 SMA200.82% SMA50-1.55% SMA200-2.59% Volume1,273,736 Change0.00%
Oct-15-20Upgrade Mizuho Neutral → Buy $19 → $24
Jul-30-20Downgrade Goldman Neutral → Sell $19 → $15
Feb-14-20Reiterated H.C. Wainwright Neutral $26 → $25
Feb-14-20Downgrade JP Morgan Overweight → Neutral $21
Feb-14-20Downgrade BofA/Merrill Buy → Neutral $31 → $20
Feb-06-20Initiated Mizuho Neutral
Jan-31-20Upgrade Wolfe Research Underperform → Peer Perform
Sep-05-19Upgrade Morgan Stanley Underweight → Equal-Weight $30 → $20
Jul-15-19Upgrade Goldman Sell → Neutral
May-31-19Initiated H.C. Wainwright Neutral
May-01-19Downgrade Citigroup Buy → Neutral
Dec-19-18Downgrade Goldman Neutral → Sell
Dec-14-18Initiated Wolfe Research Underperform
Dec-13-18Downgrade Credit Suisse Outperform → Underperform
Nov-05-18Initiated Piper Jaffray Neutral $40
Aug-07-18Initiated Stifel Hold $15 → $45
Jun-21-18Downgrade Morgan Stanley Equal-Weight → Underweight
Jun-06-18Initiated B. Riley FBR, Inc. Buy $60
May-16-18Upgrade Citigroup Neutral → Buy
May-11-18Initiated BofA/Merrill Buy $56
Oct-19-20 06:59AM  
Oct-12-20 04:12PM  
10:35AM  
Oct-09-20 05:11PM  
07:05AM  
Oct-07-20 10:14AM  
Sep-28-20 08:53PM  
Sep-25-20 11:40AM  
Sep-18-20 06:30AM  
Sep-14-20 12:06PM  
07:00AM  
Sep-13-20 08:59AM  
Sep-09-20 04:00PM  
11:40AM  
Sep-08-20 07:00AM  
Aug-28-20 11:31AM  
Aug-21-20 11:40AM  
07:00AM  
Aug-20-20 09:42AM  
Aug-19-20 07:00AM  
Aug-17-20 07:00AM  
Aug-05-20 11:40AM  
Jul-30-20 07:32PM  
11:08AM  
08:08AM  
Jul-29-20 05:30PM  
08:45AM  
07:40AM  
Jul-28-20 08:41AM  
Jul-22-20 04:00PM  
Jul-16-20 12:32PM  
Jul-13-20 10:32AM  
Jun-30-20 09:36AM  
Jun-29-20 07:00AM  
Jun-24-20 07:00AM  
Jun-22-20 09:01AM  
Jun-19-20 06:04PM  
Jun-16-20 07:28AM  
Jun-12-20 09:11AM  
Jun-08-20 09:04AM  
Jun-04-20 04:00PM  
May-29-20 11:31AM  
May-27-20 07:00AM  
May-20-20 07:00AM  
May-14-20 07:00AM  
May-11-20 07:00AM  
May-06-20 04:00PM  
May-01-20 09:45AM  
Apr-30-20 11:12AM  
Apr-29-20 03:00PM  
07:47AM  
07:00AM  
Apr-28-20 11:58AM  
11:40AM  
Apr-22-20 04:00PM  
08:49AM  
07:00AM  
Apr-16-20 12:31PM  
Apr-04-20 10:02AM  
Mar-29-20 10:25PM  
Mar-14-20 11:30AM  
Mar-04-20 07:00AM  
Feb-28-20 05:32AM  
Feb-24-20 04:00PM  
02:08PM  
Feb-19-20 04:01PM  
Feb-18-20 11:18PM  
Feb-14-20 10:49AM  
10:46AM  
Feb-13-20 09:32AM  
09:05AM  
08:05AM  
07:00AM  
05:00AM  
Feb-10-20 09:28AM  
Feb-06-20 04:00PM  
12:30PM  
Jan-29-20 09:54AM  
Jan-28-20 07:00AM  
Jan-16-20 05:50PM  
Jan-13-20 09:40AM  
05:11AM  
Jan-10-20 05:50PM  
Jan-08-20 04:00PM  
Jan-06-20 11:40AM  
Dec-30-19 10:23AM  
09:44AM  
Dec-26-19 07:22AM  
Dec-24-19 01:12PM  
Dec-20-19 05:50PM  
12:00PM  
09:28AM  
08:27AM  
08:13AM  
Dec-19-19 08:59AM  
Dec-18-19 08:50AM  
07:59AM  
Dec-17-19 10:25AM  
09:59AM  
Dec-16-19 03:55PM  
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also ALKS 3831 to treat schizophrenia; and ALKS 4230, an engineered fusion protein to expand tumor-killing immune cells and to avoid activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MITCHELL PAUL JDirectorOct 01Option Exercise14.9220,000298,40027,000Oct 02 04:40 PM
MITCHELL PAUL JDirectorOct 01Sale16.6120,000332,2627,000Oct 02 04:40 PM
ANSTICE DAVID WDirectorSep 28Option Exercise14.9220,000298,40086,213Oct 05 05:46 PM
ANSTICE DAVID WDirectorSep 28Sale16.7917,832299,31068,381Oct 05 05:46 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Jul 14Option Exercise18.115,52399,994207,345Jul 15 04:55 PM
Hopkinson Craig C.EVP R&D, Chief Medical OfficerJun 07Option Exercise0.001,250015,201Jun 08 04:21 PM
Nichols Christian ToddSVP, Chief Commercial OfficerJun 05Option Exercise0.003,50003,500Jun 08 04:19 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 14Option Exercise11.7475,000880,500834,094May 14 05:00 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMay 14Option Exercise11.7421,983258,08091,828May 14 04:58 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 14Sale15.0075,0001,125,233759,094May 14 05:00 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.May 13Option Exercise11.746,25073,37544,831May 14 04:55 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.May 13Sale15.396,25096,19338,581May 14 04:55 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 12Option Exercise11.7418,000211,320219,822May 14 04:54 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 12Sale15.7518,000283,469201,822May 14 04:54 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 07Option Exercise11.7450,000587,000809,094May 07 04:26 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 07Sale14.6350,000731,265759,094May 07 04:26 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 05Option Exercise11.7425,000293,500226,822May 07 04:25 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 05Sale14.0625,000351,425201,822May 07 04:25 PM
POPS RICHARD FDirector and CEO, Alkermes plcApr 02Option Exercise11.7450,000587,000809,094Apr 03 04:22 PM
POPS RICHARD FDirector and CEO, Alkermes plcApr 02Sale13.7950,000689,500759,094Apr 03 04:22 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 26Option Exercise11.7475,000880,500834,094Mar 26 04:38 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 26Sale14.3675,0001,077,225759,094Mar 26 04:38 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 24Option Exercise11.7425,000293,500226,822Mar 26 04:36 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 24Sale13.9125,000347,718201,822Mar 26 04:36 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 19Option Exercise11.7475,000880,500834,094Mar 19 04:10 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 19Sale14.4775,0001,085,428759,094Mar 19 04:10 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 17Option Exercise11.7425,000293,500226,822Mar 19 04:10 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 17Sale13.5425,000338,506201,822Mar 19 04:10 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Mar 02Option Exercise11.743,00035,22061,934Mar 03 04:31 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 01Option Exercise0.0017,5000766,864Mar 03 04:36 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 01Option Exercise0.004,5000201,822Mar 03 04:33 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Mar 01Option Exercise0.002,250059,596Mar 03 04:31 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMar 01Option Exercise0.004,500071,168Mar 03 04:27 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Mar 01Option Exercise0.002,250039,243Mar 03 04:23 PM
Wysenski NancyDirectorFeb 24Buy19.656,940136,37111,242Feb 25 05:15 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 21Option Exercise0.0032,4000763,750Feb 24 04:15 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 21Option Exercise0.005,8250197,322Feb 24 04:14 PM
Hopkinson Craig C.EVP R&D, Chief Medical OfficerFeb 21Option Exercise0.006,875015,955Feb 24 04:13 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 21Option Exercise0.006,875059,362Feb 24 04:12 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 21Option Exercise0.005,825068,380Feb 24 04:11 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 21Option Exercise0.004,800038,384Feb 24 04:10 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 17Option Exercise0.003,000063,459Feb 18 04:07 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 17Option Exercise0.002,500053,253Feb 18 04:09 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 17Option Exercise0.003,0000191,497Feb 18 04:11 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 17Option Exercise0.008,7500735,236Feb 18 04:12 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 17Option Exercise0.002,500034,452Feb 18 04:05 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 16Option Exercise0.002,375032,777Feb 18 04:05 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 16Option Exercise0.0018,1250734,558Feb 18 04:12 PM
Hopkinson Craig C.EVP R&D, Chief Medical OfficerFeb 16Option Exercise0.003,375010,252Feb 18 04:10 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 16Option Exercise0.003,3750188,497Feb 18 04:11 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 16Option Exercise0.003,375051,925Feb 18 04:09 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 16Option Exercise0.003,375061,631Feb 18 04:07 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 14Option Exercise9.21100,000921,000816,433Nov 15 04:08 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 14Sale19.50100,0001,950,000716,433Nov 15 04:08 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 13Option Exercise9.2120,000184,200205,122Nov 15 04:07 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 13Sale19.7020,000394,056185,122Nov 15 04:07 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 08Option Exercise9.2130,205278,188746,638Nov 08 04:06 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 08Sale19.7330,205595,827716,433Nov 08 04:06 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 07Option Exercise9.2169,795642,812786,228Nov 08 04:06 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 07Sale19.8169,7951,382,618716,433Nov 08 04:06 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 06Option Exercise9.2120,000184,200205,122Nov 08 04:04 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 06Sale19.7620,000395,116185,122Nov 08 04:04 PM